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Chronic Joint Disease Caused by Persistent Chikungunya Virus
Infection Is Controlled by the Adaptive Immune Response
David W. Hawman,a,d Kristina A. Stoermer,b,c Stephanie A. Montgomery,e Pankaj Pal,f Lauren Oko,a Michael S. Diamond,f
Thomas E. Morrisona,b
Department of Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USAa; Department of Immunology, University of Colorado School of Medicine,
Aurora, Colorado, USAb; Graduate Program in Immunology, University of Colorado School of Medicine, Aurora, Colorado, USAc; Graduate Program in Microbiology,
University of Colorado School of Medicine, Aurora, Colorado, USAd; Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina
State University, Raleigh, North Carolina, USAe; Departments of Medicine, Molecular Microbiology, and Pathology and Immunology, Washington University School of
Medicine, St. Louis, Missouri, USAf
Chikungunya virus (CHIKV) is a reemerging mosquito-borne pathogen that causes incapacitating disease in humans character-
ized by intense joint pain that can persist for weeks, months, or even years. Although there is some evidence of persistent CHIKV
infection in humans suffering from chronic rheumatologic disease symptoms, little is known about chronic disease pathogene-
sis, and no specific therapies exist for acute or chronic CHIKV disease. To investigate mechanisms of chronic CHIKV-induced
disease, we utilized a mouse model and defined the duration of CHIKV infection in tissues and the associated histopathological
changes. Although CHIKV RNAwas readily detectable in a variety of tissues very early after infection, CHIKV RNA persisted
specifically in joint-associated tissues for at least 16 weeks. Inoculation of Rag1/mice, which lack T and B cells, resulted in
higher viral levels in a variety of tissues, suggesting that adaptive immunity controls the tissue specificity and persistence of
CHIKV infection. The presence of CHIKV RNA in tissues of wild-type and Rag1/mice was associated with histopathological
evidence of synovitis, arthritis, and tendonitis; thus, CHIKV-induced persistent arthritis is not mediated primarily by adaptive
immune responses. Finally, we show that prophylactic administration of CHIKV-specific monoclonal antibodies prevented the
establishment of CHIKV persistence, whereas therapeutic administration had tissue-specific efficacy. These findings suggest that
chronic musculoskeletal tissue pathology is caused by persistent CHIKV infection and controlled by adaptive immune re-
sponses. Our results have significant implications for the development of strategies to mitigate the disease burden associated
with CHIKV infection in humans.
Chikungunya virus (CHIKV) is a mosquito-transmitted, posi-tive-sense, single-stranded RNA virus in the Alphavirus genus
of the Togaviridae family (1–3). CHIKV was first isolated from a
patient during an outbreak of febrile disease and acute crippling
joint pains in the southern province of Tanzania in 1952 and 1953
(4). Until 2004, CHIKV was known to cause debilitating rheuma-
tologic disease in many parts of Sub-Saharan Africa and Asia (5).
However, since 2004, CHIKV has caused a series of epidemics,
which began in Kenya, spread to islands in the Indian Ocean and
India, and now occur in Southeast Asia and the Pacific Region (6).
These more recent outbreaks have resulted in millions of disease
cases, and imported CHIKV infections have been reported in
nearly 40 countries, including the United States, Brazil, Japan, and
multiple European countries (7). In addition, CHIKV has adapted
to new mosquito vectors (7), which has resulted in autochthonous
transmission for the first time in several locations, including Italy,
France, New Caledonia, Papua New Guinea, and Yemen (8, 9).
This expanded epidemiology prompted the Pan American Health
Organization and the Centers for Disease Control and Prevention
to release a preparedness guide that anticipates CHIKV epidemics
in the Americas (10).
The clinical manifestations following CHIKV infection include
a sudden onset of fever, rash, intense pain in peripheral joints,
myalgia, and impaired ambulation (11). This acute stage lasts for 1
to 2 weeks and is typically followed by defervescence and conva-
lescence. However, in a subset of people infected with CHIKV,
some disease signs and symptoms, such as joint swelling, joint
stiffness, arthralgia, and tendonitis/tenosynovitis, can last for
months to years and often occur in a relapsing/fluctuating manner
(12–17). Chronic joint pain is not exclusive to CHIKV among
alphavirus family members and also is caused by related viruses,
including Sindbis (SINV), Ross River, o’nyong-nyong, and
Mayaro viruses (1). Similar to CHIKV infections, the cause of per-
sistent joint disease by these other alphaviruses is unclear; however,
there is little evidence for the development of autoimmunity in
individuals experiencing chronic disease (1, 11). Thus, an unre-
solved question in the field is whether chronic musculoskeletal
disease is associated with or caused by persistent CHIKV infec-
tion. Several studies have detected persistence of CHIKV-specific
immunoglobulin M (IgM) in humans, which is suggestive of, al-
though by no means conclusive for, the persistence of viral anti-
gens (12, 13, 18–20); however, the persistence of CHIKV-specific
IgM has not yet been associated with persistent arthralgia or joint
pathology (13). Additionally, immunohistochemical analysis of
synovial and muscle tissues from patients with chronic disease
revealed CHIKV antigen in perivascular macrophages and muscle
satellite cells as well as extensive inflammation (12, 21). More
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recently, CHIKV RNA and antigens were detected up to 90 days
postinoculation (dpi) in the spleen, lymph nodes, liver, and mus-
cle tissue of infected macaques (22). Although CHIKV was de-
tected in macaques inoculated with a range of virus doses, only
those receiving the highest doses of virus developed musculoskel-
etal disease (22).
To investigate the basis of chronic CHIKV disease, we used a
recently described mouse model in which the major disease signs
(arthritis, synovitis, and tenosynovitis) during the acute stage
were consistent with acute CHIKV disease in humans (23). Utiliz-
ing this model, we found that CHIKV RNA was cleared from
visceral tissues of wild-type (WT) mice; however, CHIKV RNA
persisted in joint-associated tissues to at least 16 weeks postinoc-
ulation (wpi). Rag1/mice, which lack mature B and T lympho-
cytes, sustained elevated levels of CHIKV RNA in joint-associated
tissues, persistence of CHIKV RNA in muscle, and persistent
viremia, suggesting that adaptive immune responses control per-
sistent CHIKV infection. The persistence of CHIKV RNA in joint-
associated tissues was associated with histopathological evidence
of arthritis, synovitis, and tendonitis. Prophylactic administration
of a combination of two highly neutralizing monoclonal antibod-
ies (MAbs; CHK-166 and CHK-152) (24) prevented Rag1/
mice from developing persistent CHIKV infection. Therapeutic
administration of these MAbs at late times postinfection had tis-
sue-specific efficacy in clearing CHIKV. Taken together, our find-
ings suggest that chronic CHIKV musculoskeletal damage may be
due to joint tissue-specific persistence of CHIKV infection. Our
findings with Rag1/ mice suggest that while the adaptive im-
mune system is necessary for CHIKV clearance from muscle tissue
and circulation, it cannot clear the virus from joint-associated
tissues. This work establishes a small-animal model of chronic
CHIKV infection that can be utilized to investigate molecular
mechanisms of chronic disease pathogenesis as well as evaluate
candidate therapies to mitigate persistent infection and joint pa-
thology.
MATERIALS AND METHODS
Viruses. The SL15649 strain of CHIKV (GenBank accession no.
GU189061) was isolated from a serum sample collected from a febrile
patient in Sri Lanka in 2006. This virus was passaged twice in Vero cells
prior to generation of an infectious cDNA clone (23). Virus stocks were
generated as previously described (23, 25). Stock virus titers were quanti-
fied by plaque assay on BHK-21 cells as previously described (23, 25).
CHIKV strains 37997 and PO731460 were gifts of Ann Powers (Centers
for Disease Control and Prevention, Fort Collins, CO). The PO731460
strain (GenBank accession no. HM045788) was isolated from a human
patient in India in 1973 and passaged twice in Vero cells (6). The 37997
strain (GenBank accession no. AY726732) was isolated fromAedes furcifer
mosquitoes in Senegal in 1983. This virus was passaged once in Aedes
pseudoscutellaris (AP-61) cells and twice in Vero cells (26). Stock
PO731460 and 37997 viruses were produced after a single passage in
BHK-21 cells as previously described (27).
Mouse experiments. C57BL/6J WT mice (stock number 000664) and
congenic Rag1/ mice (stock number 002216) were obtained from the
Jackson Laboratory and bred in specific-pathogen-free facilities at the
University of Colorado. Animal husbandry and experiments were per-
formed in accordance and with approval of the University of Colorado
School of Medicine Institutional Animal Care and Use Committee guide-
lines. All mouse infection studies were performed in an animal biosafety
level 3 laboratory. Three-week-old mice were used for all studies. Mice
were inoculated in the left rear footpad with 103 PFU of virus in diluent
(phosphate-buffered saline [PBS] supplemented with 1% fetal bovine se-
rum [FBS]) in a volume of 10l. Mock-infected animals received diluent
alone. Mice were monitored for disease signs and weighed at 24-hour
intervals. On the termination day of each experiment, mice were sedated
with isoflurane and euthanized by thoracotomy and exsanguination,
blood was collected, and mice were perfused by intracardiac injection of
1 PBS or 4% paraformaldehyde, depending on the experiment. PBS-
perfused tissues were removed by dissection and homogenized in TRIzol
reagent (Life Technologies) for RNA isolation or PBS-1% FBS for tissue
titers using a MagNA Lyser (Roche). For prophylaxis studies, MAbs (200
g each of CHK-152 and CHK-166 [24] or 400 g of WNV E16 [anti-
West Nile virus E protein MAb] [28]) were administered by intraperito-
neal (i.p.) inoculation on days 1 and 3 as previously described (24).
For therapeutic studies, MAbs were administered on days21 and25.
Real-timeRT-qPCR.RNA was isolated using a PureLink RNA minikit
(Life Technologies), and the amounts of CHIKV positive-strand RNA
present in tissues were quantified as previously described (25). Briefly, a
CHIKV-specific primer (CHIKV1036, 5=-ggcagtatcgtgaattcgatgcCGTGT
CGGTAGTCTTGCACAT-3=; lowercase letters indicate that this region of
the primer sequence is not complementary to the CHIKV sequence) was
used to prime reverse transcription. CHIKV sequence-specific forward
(CHIKV874, 5=-AAAGGGCAAACTCAGCTTCAC-3=) and reverse
(CHIKV961, 5=-GCCTGGGCTCATCGTTATTC-3=) primers were used
with an internal TaqMan probe (CHIKV899, 5=-6-carboxyfluorescein [F
AM]-CGCTGTGATACAGTGGTTTCGTGTG-MGB-3=) that amplified
a region in the nsP1 gene for quantitative PCR on a LightCycler 480
(Roche). Samples from mock-infected mice served to ensure assay speci-
ficity. For absolute quantification of CHIKV RNA, a standard curve was
generated: 10-fold dilutions from 108 to 100 copies of CHIKV positive-
strand genomic RNA, synthesized in vitro, were spiked into RNA from
BHK-21 cells, and reverse transcription (RT) and quantitative PCR
(qPCR) were performed in an identical manner. No template controls
were run in parallel. To quantify CHIKV RNA from multiple CHIKV
genotypes, a modified RT-qPCR assay was designed. In this assay, the
first-strand cDNA reaction was primed with 250 ng of random primers
(Life Technologies). A CHIKV sequence-specific forward primer
(CHIKV2411, 5=-AGAGACCAGTCGACGTGTTGTAC-3=) and a
CHIKV sequence-specific reverse primer (CHIKV2676, 5=-GTGCGCAT
TTTGCCTTCGTA-3=) were used in conjunction with a CHIKV se-
quence-specific TaqMan probe (CHIKV2579, 5=-FAM-ATCTGCACCCA
AGTGTACCA-MGB-3=). A random primed cDNA standard curve was
generated as described above. To quantify the CHIKV subgenomic 26S
mRNA, random primed cDNA was used as a template for CHIKV se-
quence-specific forward (CHIKV10239, 5=-CGGCGTCTACCCATTTAT
GT-3=) and CHIKV sequence-specific reverse (CHIKV10363, 5=-CCCTG
TATGCTGATGCAAATTC-3=) primers and a CHIKV sequence-specific
TaqMan probe (CHIKV10290, 5=-FAM-AAACACGCAGTTGAGCGAA
GCAC-MGB-3=) that amplified a region in the E1 gene. The nsP1 gene
copy number was determined in parallel with random primed cDNA and
the primers/probe described above. The data were expressed as a ratio of
the E1 gene copy number divided by the nsP1 gene copy number.
Viral plaque assays. Serial 10-fold dilutions of virus-containing sam-
ples were adsorbed on BHK-21 cells for 1 h at 37°C, followed by an overlay
with 0.5% immunodiffusion agarose (MP Biomedicals) in medium for 38
to 40 h. Plaques were visualized by neutral red staining (Sigma). Plaque
numbers were enumerated to determine the number of PFU/ml of culture
supernatant and mouse serum or PFU/g of tissue.
Histopathological analysis. At specific times, mice were sacrificed
and perfused by intracardiac injection of 4% paraformaldehyde, pH 7.3,
and the indicated tissues were dissected and fixed in 4% paraformalde-
hyde, pH 7.3. Tissues were embedded in paraffin, and 5-m sections were
prepared. Tissue sections were stained with hematoxylin and eosin (H&E)
and evaluated by light microscopy. Two anatomic pathologists blindly
scored the presence, distribution, and severity of histological lesions. For
all tissue changes, a scoring system was developed as follows: 0, absent; 1,
minimal, less than 10% of tissue affected; 2, mild, 10 to 24% of tissue
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affected; 3, moderate, 25 to 39% of tissue affected; 4, marked, 40 to 59% of
tissue affected; 5, severe, greater than 60% of tissue affected.
Statistical analysis. All data were analyzed using GraphPad Prism 5
software. Data were evaluated for significant differences using either a
two-tailed, unpaired t test with or without Welch’s correction, a Mann-
Whitney test, a one-way analysis of variance (ANOVA) followed by
Tukey’s multiple comparison test, or a two-way ANOVA followed by
Bonferroni posttest analysis. A P value of 0.05 was considered statisti-
cally significant. All differences not indicated as significant had P values of
0.05.
RESULTS
Persistence of CHIKV is tissue specific. To evaluate the duration
of CHIKV infection in tissues, we utilized a WT C57BL/6 mouse
model in which the major pathological findings during the acute
stage of infection (arthritis, myositis, and tenosynovitis) were con-
sistent with the disease in infected humans (23, 29). WT mice were
inoculated subcutaneously in the left rear footpad with virus dil-
uent only (mock) or 103 PFU of CHIKV strain SL15649. For many
of the experiments, we monitored CHIKV infection in tissues us-
ing a highly sensitive and specific RT-qPCR assay. Following ex-
tensive intracardiac perfusion with PBS, positive-strand genomic
CHIKV RNA burdens in the ankles and spleen at 3 dpi (n 7) and
1 (n 11), 2 (n 8), 4 (n 11), 6 (n 7), 12 (n 8), and 16 (n
3) weeks postinoculation (wpi) were quantified by RT-qPCR with
primers and probes complementary to sequences in the viral nsP1
gene coding region (Fig. 1A and Table 1). CHIKV RNA in tissues
of mock-inoculated mice was below the limit of detection of this
assay (data not shown), which confirmed the specificity of our
measurements. The amount of CHIKV RNA in ankle-associated
tissues of CHIKV-inoculated mice was highest at 3 dpi and de-
clined during the first 2 to 4 weeks postinoculation. CHIKV RNA
was detected in the left ankles of all mice, which is near the site of
inoculation, for at least 16 wpi. CHIKV RNA also was detected in
the right ankles of nearly all mice, a tissue distal to the site of
inoculation, for at least 16 wpi. In addition to ankle-associated
tissues, CHIKV RNA was measured at a low level in the spleen of
WT mice (Fig. 1A and Table 1); however, levels in the spleen
waned such that after 6 wpi, CHIKV RNA was undetectable.
CHIKV RNA also persisted in the wrists of WT mice (Table 1),
suggesting that CHIKV may establish persistent infections prefer-
entially in joint-associated tissues.
To evaluate further the tissue specificity of CHIKV RNA per-
sistence, we quantified viral RNA levels in the serum (Fig. 1B),
quadriceps muscles (Fig. 1C and D), liver (Fig. 1E), brain (Fig. 1F),
and spinal cord (Fig. 1G) at 3, 14, and 28 dpi by RT-qPCR. CHIKV
RNA was readily detected in these tissues at 3 dpi, a time point
during the acute stage of infection. Consistent with the musculo-
skeletal tissue tropism of CHIKV and related arthritogenic alpha-
viruses (30, 31), the highest CHIKV RNA burdens during the
acute stage (3 dpi) were present in joint-associated and skeletal
muscle tissues (Fig. 1). In contrast to the ankles and spleen,
CHIKV RNA was cleared rapidly from the serum, quadriceps
muscles, liver, brain, and spinal cord of WT mice (Fig. 1 and Table
1). These findings indicate that persistence of CHIKV RNA fol-
lowing a subcutaneous inoculation is joint tissue specific.
CHIKV RNA persists in mice inoculated with East/Central/
South African, West African, and Asian CHIKV strains. Phylo-
genetic analyses have identified three genotypes of CHIKV strains:
East/Central/South African (ECSA), West African, and Asian (6,
32). To determine if persistence of viral RNA in joint-associated
tissues was specific to CHIKV strain SL15649, a member of the
ECSA genotype, we tested two distantly related CHIKV strains:
Asian strain PO731460 and West African strain 37997 (6). WT
C57BL/6 mice were inoculated subcutaneously in the left rear
FIG 1 CHIKV RNA persists in joint-associated tissue and spleen of WT mice.
Three-week-old WT C57BL/6 mice were mock inoculated (data not shown) or
inoculated with 103 PFU of CHIKV by injection in the left rear footpad. Mice
were sacrificed and perfused by intracardiac injection with PBS, and total RNA
was isolated from the indicated tissues. (A) At 3 dpi (n 7 mice) and 1 (n
11), 2 (n 8), 4 (n 11), 6 (n 7), 12 (n 8), and 16 (n 3) wpi, CHIKV
RNA in the ankles and spleen was quantified by RT-qPCR. Each data point
represents the arithmetic mean	 standard errors of the means (SEM), and the
dashed line indicates the limit of detection. (B to G) At 3 (n 7), 14 (n 3 to
7), and 28 dpi (n 3 to 5), CHIKV RNA in the serum (B), left quad (C), right
quad (D), liver (E), brain (F), and spinal cord (G) was quantified by RT-qPCR.
Horizontal lines indicate the means, and dashed lines indicate the limits of
detection. Data shown are derived from 2 to 3 independent experiments, ex-
cept data for 16 wpi, which were derived from a single experiment.
Hawman et al.
13880 jvi.asm.org Journal of Virology
 o
n
 D
ecem
ber 4, 2013 by W
ashington University in St. Louis
http://jvi.asm.org/
D
ow
nloaded from
 
footpad with 103 PFU of either CHIKV strain. Following extensive
intracardiac perfusion with PBS, viral RNA levels in the left and
right ankles at 4 wpi (n  6) were quantified by RT-qPCR. As
shown in Fig. 2, the amount of CHIKV RNA in ankle-associated
tissues at 4 wpi in mice inoculated with strain 37997 or strain
PO731460 was similar to or higher than that detected in ankle
tissues of mice inoculated with strain SL15649. These data indicate
that CHIKV strains from all described genotypes can establish
persistent infections in murine joint tissue and, thus, this is not an
unusual property of the recent ECSA epidemic strains.
Adaptive immunity controls persistence of CHIKV. Chronic
arthritis could be caused by persistent viral infection and/or per-
sistent immunopathology associated with B and T cell immunity.
To evaluate whether the adaptive immune response controls or
contributes to CHIKV-induced joint disease and also impacts the
tissue specificity of CHIKV persistence, Rag1/mice, which lack
mature B and T lymphocytes (33), were inoculated subcutane-
ously in the left rear footpad with 103 PFU of CHIKV SL15649.
The levels of CHIKV RNA in perfused tissues (ankles, quadriceps
muscles, and spleen) at 3 dpi and 1, 2, 4, 6, and 12 wpi were
quantified by RT-qPCR (Fig. 3A to E). The levels of CHIKV RNA
were elevated in both the left ankle joint (11-fold [P  0.001],
4-fold [P 0.05], 12-fold [P 0.05], 6-fold [P 0.01], and 7-fold
[P  0.001] at 1, 2, 4, 6, and 12 wpi, respectively) and the right
ankle joint (15-fold [P 0.001], 32-fold [P 0.001], 23-fold [P
0.001], 26-fold [P 0.001], and 404-fold [P 0.001] at 3 dpi and
1, 4, 6, and 12 wpi, respectively) of Rag1/ mice compared to
those in WT mice (Fig. 3A and B). These data indicate that T
and/or B cell immunity contributes to the control of CHIKV in-
fection in joint tissues but is not sufficient to mediate complete
clearance. CHIKV RNA persisted in quadriceps muscle tissues of
Rag1/mice for at least 12 wpi but was cleared by 2 wpi from the
same tissues of WT mice (Fig. 3C and D); thus, in contrast to the
joint tissues, adaptive T and/or B cell immunity was sufficient to
clear CHIKV from muscle tissues. Although the amounts of
CHIKV RNA detected in the spleens of WT and Rag1/ mice
were similar at 3 dpi and 1 wpi, remarkably, viral RNA persisted in
the spleen of WT mice for 6 wpi but fell below the limit of detec-
tion in the spleen of Rag1/ mice at 2, 4, 6, and 12 wpi (Fig. 3E).
These data suggest that the altered organization and/or cellularity
of the spleen of Rag1/mice (34) prevents CHIKV persistence in
this tissue; alternatively, although it has not been reported,
CHIKV could have a limited tropism for subsets of B and T cells.
We also quantified the amounts of infectious virus in the serum of
CHIKV-inoculated WT and Rag1/ mice via direct plaque as-
says. Infectious CHIKV was present in sera from both mouse
strains at 3 dpi (Fig. 3F) but was not detected in sera of WT mice at
any of the later time points evaluated. In contrast, Rag1/ mice
developed a persistent low level of viremia (Fig. 3F), which
showed a pattern of fluctuation. A rapid decline in titer occurred
between 3 and 7 dpi that was followed by a rise in titer between 1
and 2 wpi. Another drop in titer occurred at 4 wpi prior to the
establishment of a steady-state level by 6 wpi. These data are con-
sistent with recent studies showing that Rag2/ mice and B cell-
deficient mice developed a persistent viremia following CHIKV
inoculation (35, 36). Taken together, these analyses suggest that
adaptive immune responses modulate persistent CHIKV infec-
tion in a tissue-specific manner.
During the alphavirus replication cycle, a 26S positive-sense
subgenomic RNA, colinear with the 3= one-third of the full-length
genomic RNA, is synthesized from the 26S subgenomic promoter
(37, 38). The 26S subgenomic RNA is synthesized in 3- to 10-fold
molar excess of the full-length positive-strand genomic RNA;
TABLE 1 CHIKV infection in tissues of infected animals
Mouse
strain
Tissue or
seruma
No. of positive tissues/total number of tissues by
day postinoculationb
3 7 14 28 42 84 112
WT Left ankle 7/7 11/11 12/12 11/11 7/7 8/8 3/3
Right ankle 7/7 11/11 8/8 9/9 7/7 5/8 3/3
Left wrist ND ND 5/5 ND ND ND 2/3
Right wrist ND ND ND ND ND ND 1/3
Left quad 7/7 1/11 0/8 1/6 0/3 0/5 ND
Right quad 7/7 5/11 0/8 0/9 0/3 0/5 ND
Spleen 7/7 6/11 4/7 6/11 3/7 0/8 0/3
Liver 7/7 ND 0/3 0/3 ND ND ND
Brain 5/7 ND 1/3 0/3 ND ND ND
Spinal cord 6/7 ND 1/3 0/3 ND ND ND
Serum 6/6 0/6 0/6 0/6 0/6 0/6 ND
Rag1/ Left ankle 6/6 6/6 9/9 6/6 7/7 5/5 ND
Right ankle 6/6 6/6 9/9 6/6 7/7 5/5 ND
Left quad 6/6 6/6 9/9 6/6 7/7 5/5 ND
Right quad 6/6 6/6 9/9 6/6 7/7 5/5 ND
Spleen 6/6 1/6 0/9 0/6 0/7 0/5 ND
Liver 6/6 ND 0/3 0/6 0/5 ND ND
Brain 6/6 ND ND 2/6 0/5 ND ND
Serum 5/5 2/6 5/5 4/6 6/6 4/4 ND
a Tissues were analyzed for CHIKV positive-strand RNA via RT-qPCR. Limit of
detection was 100 CHIKV RNA copies/g of RNA. Serum was analyzed for infectious
virus via direct plaque assays. Limit of detection was 50 PFU/ml of serum.
b Data are expressed as the number of tissues that were CHIKV positive divided by the
total number of tissues analyzed. Each tissue was from an independent mouse. ND, not
done.
FIG 2 Persistence of CHIKV RNA in joint-associated tissue is virus genotype
independent. Three-week-old WT C57BL/6 mice were inoculated with 103
PFU of CHIKV strain 37997 or strain PO731460 by injection in the left rear
footpad (n  6 or 7/group). At 28 dpi, mice were sacrificed and perfused by
intracardiac injection with PBS, and total RNA was isolated from the indicated
tissues. CHIKV RNA in the left ankle (A) and right ankle (B) was quantified by
RT-qPCR. Levels of CHIKV RNA from mice inoculated with 103 PFU of
CHIKV strain SL15649 were quantified by the same assay for comparison.
Horizontal lines indicate the means, and dashed lines indicate the limits of
detection. *, P  0.05; **, P  0.01, as determined by one-way ANOVA fol-
lowed by Tukey’s multiple comparison test. Data shown are derived from two
independent experiments.
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thus, quantification of this molar excess can be used as an indica-
tor of ongoing alphavirus replication (39–43). We designed an
additional sequence-specific RT-qPCR assay with primers and
probes complementary to sequences in the E1 coding region
which, in contrast to those in the nsP1 gene coding region, are
found in both the full-length and subgenomic RNAs produced in
infected cells. This assay amplified full-length CHIKV positive-
strand genomic RNA with similar efficiency as our nsP1 gene-
based assay (data not shown). Utilizing this assay in combination
with our nsP1 gene-based assay, we detected a 2.6- to 4.3-fold
excess of CHIKV RNA with our E1-based assay in the ankle tissues
of WT and Rag1/ mice at 3 dpi (Fig. 4A and B), suggesting
similar levels of replication in these tissues at this time point. The
E1 RNA/nsP1 RNA ratios declined from 3 dpi to 4 wpi in the left
ankle tissues of WT mice (P 0.001) to an average ratio of 1.2 at
4 wpi and then increased at 6 wpi (P 0.001) (Fig. 4A). Similarly,
the E1 RNA/nsP1 RNA ratios declined or remained constant over
time in the right ankle of WT mice (Fig. 4B). These data suggest
that CHIKV replication was restricted in the joint tissues of WT
mice during persistence. In contrast, the excess of RNA detected
with the E1-based assay increased over time in both the left ankle
(P 0.05) and right ankle (P 0.001) of Rag1/ mice to levels
that were higher than those of WT mice, suggesting higher levels
of CHIKV replication occurred in joint tissues of Rag1/ mice
than in WT mice during persistence. Consistent with these results,
infectious CHIKV was detected in ankle joint tissues of Rag1/
but not WT mice at 42 dpi by direct plaque assay (Fig. 4C and data
not shown). These data suggest that CHIKV RNA replication oc-
curs at low, fluctuating levels in joint-associated tissues of WT
mice and further support an important role for adaptive immu-
nity in controlling persistent CHIKV infection.
Persistence of CHIKV is associated with pathology. The data
presented thus far suggest that CHIKV RNA persists in mice pref-
erentially in joint-associated tissues. To determine the extent to
which the detection of CHIKV RNA is associated with pathology,
histological changes in musculoskeletal tissues of uninfected con-
trol mice and CHIKV-infected mice at various times postinocula-
tion were evaluated in a blinded manner. Consistent with prior
reports (23, 29), arthritis, synovitis, tendonitis, myositis, and
myocyte necrosis were most severe during the acute stage (7
dpi) (Fig. 5A to F). Histopathology scores for synovitis (Fig. 5B),
arthritis (Fig. 5C), and myositis (Fig. 5D) during the acute stage
appeared more severe for WT mice than for Rag1/ mice, con-
sistent with studies reporting a possible pathogenic role of CD4
T cells in acute CHIKV-induced disease (36). At this time point,
both WT and Rag1/ mice had an infiltrating inflammatory cell
population predominantly composed of macrophages and neu-
trophils with admixed lymphocytes. At late times postinoculation
(4 to 12 wpi), most WT (8 of 11) and Rag1/ (6 of 9) mice had
apparent synovitis (Fig. 5A and B). However, arthritis (Fig. 5C),
metatarsal muscle inflammation (Fig. 5D), metatarsal muscle
necrosis (Fig. 5E), and tendonitis (Fig. 5F) resolved in WT mice
but remained evident in the majority of Rag1/ mice at 12 wpi.
During this chronic stage, the infiltrating inflammatory cell pop-
ulation in tissues of WT mice consisted predominantly of histio-
cytes and lymphocytes, whereas histiocytes and neutrophils were
predominant in the tissues of Rag1/mice. Thus, the persistence
of CHIKV RNA is associated with pathology in joint-associated
tissues, muscle tissue, and tendons. Moreover, T and/or B cell
responses appear to prevent the development of more severe
chronic disease likely due to their ability to control infection.
Nonetheless, synovitis failed to resolve in WT mice for at least 12
wpi, which correlated with the joint tissue-specific persistence of
CHIKV RNA (Fig. 1 and Table 1).
FIG 3 CHIKV persistence in tissues of Rag1/ mice. Three-week-old Rag1/
congenic C57BL/6 mice were mock inoculated (data not shown) or inoculated
with 103 PFU of CHIKV by injection in the left rear footpad. At 3 dpi (n 6) and
1 (n 6), 2 (n 9), 4 (n 6), 6 (n 9), and 12 wpi (n 5), mice were sacrificed
and perfused by intracardial injection with 1 PBS, and total RNA was isolated
from the left ankle (A), right ankle (B), left quadriceps muscle (C), right quadriceps
muscle (D), and spleen (E). Levels of CHIKV RNA were quantified by RT-qPCR.
For comparison, values were plotted against values in WT mice. (F) Serum was
analyzed for infectious virus via direct plaque assays. Dashed lines indicate the
limit of detection. *, P  0.05; **, P  0.01; ***, P  0.001, as determined by
two-way ANOVA followed by Bonferroni posttest analysis. Data shown are de-
rived from at least two independent experiments.
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MAb prophylaxis prevents persistence of CHIKV in tissues
ofRag1/mice. The studies described thus far establish a mouse
model that can be used for evaluating the efficacy of therapeutic
agents against chronic CHIKV infection and joint disease. Re-
cently, a combination of two CHIKV MAbs, CHK-152 and CHK-
166 (which recognize discrete epitopes on CHIKV E2 and E1,
respectively), was shown to have therapeutic efficacy in murine
models of lethal CHIKV infection and acute CHIKV-induced
musculoskeletal disease (24). To evaluate whether these neutral-
izing MAbs could prevent persistent CHIKV infection, 200 g
each of CHK-152 and CHK-166 or 400 g of a negative control
MAb (WNV E16) was administered intraperitoneally to Rag1/
mice 1 day before and 3 days after inoculation with CHIKV. Per-
sistence of CHIKV was evaluated at 28 days after virus inocula-
tion. Prophylaxis with CHK-152 and CHK-166 reduced levels of
infectious CHIKV in the serum to below the limit of detection
(Fig. 6A; P  0.03). In addition, prophylaxis with CHK-152 and
CHK-166 reduced CHIKV RNA levels in the left ankle (P 0.02)
and right ankle (P 0.01) to below the limits of detection in 3/5
and 4/5 mice, respectively (Fig. 6B and C). In the two mice that
were positive in these tissues, CHIKV RNA levels were reduced by
99% compared to those in mice treated with the negative-con-
trol MAb.
MAb therapy has tissue-specific effects on persistent CHIKV
infection. To evaluate whether the neutralizing anti-CHIKV
MAbs could reduce or eliminate an established persistent infec-
tion, 200 g each of CHK-152 and CHK-166 or 400 g of a neg-
ative-control MAb (WNV E16) was administered intraperitone-
ally to Rag1/ mice on days 21 and 25 post-CHIKV inoculation,
and viral burdens were evaluated at 28 dpi. As shown in Fig. 6D,
therapeutic administration of CHK-152 and CHK-166 eliminated
infectious virus from the sera (P  0.01). In addition, while we
detected infectious CHIKV in the quadriceps of 2/3 mice treated
with the control MAb, 0/3 mice treated with CHK-152 and CHK-
166 had detectable infectious virus (data not shown), suggesting
that the CHIKV-specific MAbs could eliminate infectious virus in
musculoskeletal tissues. This treatment regimen, however, had no
effect on viral RNA levels in the left ankle (Fig. 6E) or the quadri-
ceps muscles (data not shown), although a significant, albeit small
(3.2-fold, P  0.01), reduction of CHIKV RNA was observed in
the right ankle (Fig. 6F). In addition, the E1 RNA/nsP1 RNA ratio
in the right ankle was reduced in mice treated with CHK-152 and
CHK-166 compared to mice treated with the control antibody
(P 0.001) (Fig. 6G), suggesting that the CHIKV-specific MAbs
reduced virus replication in this tissue. Thus, this two-dose,
1-week combination MAb therapy was sufficient to reduce bur-
dens of infectious virus, although a more extended regimen may
be required to clear CHIKV from some tissues.
DISCUSSION
A defining feature of alphavirus-induced musculoskeletal disease
is the development of chronic polyarthralgia and/or polyarthritis,
which can be debilitating (1, 17). The underlying processes that
result in chronic disease associated with these infections are not
well understood. Here, we utilized a recently developed mouse
model of acute CHIKV-induced musculoskeletal disease (23) to
investigate the sites and duration of CHIKV infection and muscu-
loskeletal tissue pathology, the role of adaptive immunity in con-
trol of persistent infection, and a possible strategy to prevent or
cure persistent infection. Our findings suggest that CHIKV estab-
lishes persistent infections in joint-associated tissues, that persis-
tence of CHIKV RNA is associated with ongoing synovitis, and
that the sites of CHIKV persistence and tissue burdens of CHIKV
are controlled by adaptive immunity. We also found that an anti-
body-based treatment prevents persistent CHIKV infection when
administered as prophylaxis and has tissue-specific effects when
administered therapeutically. Together, these studies support the
hypothesis that chronic CHIKV arthritic disease is associated with
FIG 4 Increased subgenomic mRNA in tissues of Rag1/mice. CHIKV RNA in the left ankle (A) and right ankle (B) of WT and Rag1/ C57BL/6 mice at the
indicated time points was quantified by RT-qPCR assays specific for nucleotide sequences in the nsP1 and the E1 genes in parallel as described in Materials and
Methods. The E1/nsP1 ratio was plotted as an indirect measurement of subgenomic mRNA production. *, P 0.05; **, P 0.01; ***, P 0.001, as determined
by one-way ANOVA followed by Tukey’s multiple comparison test. (C) Infectious virus in the left and right ankles of Rag1/ C57BL/6 mice at 42 dpi was
quantified by direct plaque assay. Dashed line indicates the limit of detection. Data shown are derived from at least two independent experiments.
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persistent infection and establishes a small-animal model that can
be utilized to investigate molecular mechanisms of chronic disease
and test therapies that mitigate persistent CHIKV infection and
joint pathology.
Persistence of CHIKV RNA is joint tissue specific and con-
trolled by adaptive immunity. Persistence of alphaviruses in ver-
tebrate hosts was first noted in the central nervous system of both
WT and scid mice inoculated intracerebrally (i.c.) with neuroad-
apted SINV (44, 45). Subsequent studies established that persis-
tent central nervous system (CNS) infection with SINV following
an i.c. inoculation was controlled by gamma interferon (IFN-
)
production by T cells and anti-SINV antibodies produced by an-
tibody-secreting B cells residing in the CNS (46–49). In our stud-
ies, we found that persistence of CHIKV RNA in WT mice was
joint tissue specific, with high levels of viral RNA detected in ankle
and wrist tissues, but not in several other tissues, for at least 16
wpi. Our studies also indicated that the establishment of persistent
infection in joint-associated tissues of mice is a common property
shared by CHIKV strains from all three genotypes. These data are
consistent with epidemiological studies which have documented
the development of protracted disease symptoms during out-
breaks of CHIKV in humans involving any of the three CHIKV
genotypes (5). The detection of CHIKV RNA in joint-associated
tissues is also consistent with previous studies in humans in which
FIG5 Chronic synovitis in WT andRag1/mice. Three week-old WT andRag1/C57BL/6 mice were mock inoculated or inoculated with 103 PFU of CHIKV
by injection in the left rear footpad. (A) At 7 and 42 dpi, 5-m paraffin-embedded sections were generated from the hind limbs and stained with hematoxylin and
eosin. Arrows indicate areas of synovitis, as identified by an anatomic pathologist. Scale bar, 200M. Images are representative of three mice per group. (B to F)
At 1, 4, 6, and 12 wpi, 5-m paraffin-embedded sections were generated from the hind limbs, stained with hematoxylin and eosin, and scored in a blinded manner
by two anatomic pathologists for the degree of synovitis (B), arthritis (C), metatarsal muscle inflammation (D), metatarsal muscle necrosis (E), and tendonitis
(F) based on the following scale for percentage of tissue affected: 0, absent (0%); 1, minimal (10%); 2, mild (11 to 25%); 3, moderate (26 to 40%); 4, marked
(41 to 60%); and 5, severe (60%).
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CHIKV antigen was detected in synovial biopsy specimens col-
lected from a patient with chronic disease (12) and in experimen-
tally inoculated rhesus and cynomolgous macaques in which
CHIKV RNA was detected in joints at later times postinoculation
(22, 50). Analogously, Ross River virus RNA has been detected in
knee biopsy specimens collected from patients 5 weeks after the
onset of joint symptoms (51).
Similar to WT mice, Rag1/mice failed to clear CHIKV RNA
from ankle joint-associated tissues. However, the amounts of
CHIKV RNA and the E1/nsP1 RNA ratio in ankle joint-associated
tissues of Rag1/ mice were elevated compared to those of WT
mice, suggesting that adaptive immunity limits viral burden in
these tissues. In contrast, WT but not Rag1/ mice rapidly
cleared CHIKV RNA from quadriceps muscle tissue and infec-
tious virus from the serum. Collectively, these data suggest that T
and/or B cell-mediated immunity controls CHIKV burdens in a
tissue-specific manner.
Persistence of CHIKV RNA is associated with chronic syno-
vitis. Similar to acute CHIKV rheumatological disease in WT
mice, inoculation of Rag1/ mice with CHIKV resulted in syno-
vitis, arthritis, myositis, and tendonitis; thus, CHIKV can induce
an acute inflammatory response despite the lack of mature T and
B cells. These findings are similar to studies in Rag1/ mice in-
fected with Ross River virus in which affected joints and muscles
were infiltrated with macrophages and NK cells (31). However,
our detailed assessment of tissue sections at 7 dpi revealed that
Rag1/mice had less severe tissue pathology than WT mice dur-
ing the acute stage, suggesting an early pathogenic role for T
FIG 6 Efficacy of MAb prophylaxis and therapy against persistent CHIKV infection in Rag1/ mice. (A to C) Three-week-old Rag1/ C57BL/6 mice were
injected i.p. with 400 g of WNV E16 MAb or 200 g CHK-152 and 200 g CHK-166 MAbs on days1 and3. On day 0, mice were inoculated with 103 PFU
of CHIKV in the left rear footpad. At 28 dpi, mice were sacrificed and perfused with PBS via intracardiac injection, and infectious virus in the serum (A) was
quantified by plaque assay. Tissues (left ankle/foot [B] and right ankle/foot [C]) were homogenized in TRIzol, and CHIKV RNA was quantified by RT-qPCR.
Horizontal lines indicate the means, and dashed lines indicate the limits of detection. P values were determined by Mann-Whitney tests. Data are from two
independent experiments. (D to G) Three-week-old Rag1/C57BL/6 mice were inoculated with 103 PFU of CHIKV in the left rear footpad. On days 21 and 25,
mice were injected i.p. with 400 g of WNV E16 MAb or 200 g CHK-152 and 200 g CHK-166 MAbs. At 28 dpi, mice were sacrificed and perfused with PBS
via intracardiac injection. (D) Infectious virus in the serum was quantified by plaque assay. The left ankle (E) and right ankle (F) were homogenized in TRIzol,
and CHIKV RNA was quantified by RT-qPCR. (G) CHIKV RNA in the right ankle was quantified by RT-qPCR assays specific for nucleotide sequences in the nsP1
and the E1 genes in parallel as described in Materials and Methods. The E1/nsP1 ratio was plotted as an indirect measurement of subgenomic mRNA production.
Horizontal bars indicate the means, and dashed lines indicate the limits of detection. P values were determined by the Mann-Whitney test (D) or two-tailed
unpaired t tests (F and G). Data are from two independent experiments.
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and/or B cells. These findings agree with studies reporting less
severe foot swelling in CHIKV-infected Rag2/ mice and major
histocompatibility complex class II (MHC-II)-deficient mice (36,
52). More specifically, CD4 T cells were shown to contribute to
CHIKV-induced foot swelling and musculoskeletal tissue injury
(36).
Assessment of tissue sections from WT and Rag1/mice at 4,
6, and 12 wpi revealed that CHIKV infection resulted in a low-
level, chronic synovitis. Intraarticular injection of dsRNA directly
into murine joint spaces also is arthritogenic (53), suggesting that
viral RNA may be sufficient to cause joint inflammation and in-
jury. Thus, persistence of CHIKV in joint-associated tissues may
promote chronic inflammation of synovial membranes. In con-
trast, arthritis, myositis, and tendonitis resolved in the majority of
WT mice, but not in Rag1/ mice, between 4 and 12 wpi. Al-
though Rag1/ mice had less severe acute disease, in the chronic
phase, arthritis, myositis, myocyte necrosis, and tendonitis were
present in the majority of Rag1/mice. These longitudinal anal-
yses suggest that functional T and/or B cell responses protect
against chronic musculoskeletal disease. Our results are consistent
with recent findings in rhesus macaques in which persistence of
CHIKV in the spleen correlated with defects in adaptive immune
responses (54) and with findings in humans in which the rapid
appearance of neutralizing IgG3 antibodies correlated with viral
clearance and protection from chronic CHIKV disease (55).
Prophylaxis with CHIKV-specific MAbs prevents CHIKV
persistence. Prophylaxis via passive transfer of human immune
plasma or CHIKV IgG to highly susceptible Ifnar1/ mice can
protect against CHIKV-induced mortality, suggesting that anti-
body therapy may be a promising disease prevention option for
individuals at high risk of CHIKV infection (56). More recently,
prophylaxis with different CHIKV-specific MAbs was shown to
protect against lethal CHIKV infection in AGR129 mice (57),
which lack receptors for type I and type II interferons as well as
Rag2, and also in Ifnar1/ mice (24). Importantly, prophylaxis
with CHIKV-specific MAbs prevented acute joint swelling and
inflammatory arthritis in CHIKV-infected WT mice (24). How-
ever, none of these previous studies addressed whether antibody-
based prophylaxis or treatment could impact persistent CHIKV
infection. We found that the combination of two neutralizing
MAbs (CHK-152 and CHK-166), which recognize discrete
epitopes on CHIKV E2 and E1, respectively, prevented persistent
infection in Rag1/mice when administered as prophylaxis. To-
gether with previous reports, our findings suggest that antibody-
based prophylaxis in targeted at-risk populations may be a prom-
ising strategy to prevent both acute and chronic CHIKV disease.
MAb therapy after the establishment of persistence enables
tissue-specific clearance. To test whether the neutralizing anti-
CHIKV MAbs could reduce or eliminate an established persistent
CHIKV infection, we treated persistently infected Rag1/mice 3
weeks after CHIKV inoculation with two doses of MAbs and eval-
uated viral burden 1 week later. Similar to the prophylaxis results,
therapeutic administration of CHK-152 and CHK-166 eliminated
infectious virus in the sera. MAb treatment also prevented recov-
ery of infectious virus from quadriceps muscle tissue, suggesting
that infectious virus in at least some tissues is efficiently eliminated
upon treatment. In contrast to prophylaxis, therapeutic adminis-
tration of CHK-152 and CHK-166 had minimal effects on CHIKV
RNA burdens in joint-associated tissues and quadriceps muscle
tissue. These findings are similar to those of a study showing that
a single dose of an anti-SINV virus MAb administered at 7 days
postinfection failed to eliminate virus RNA in the CNS of scidmice
(45). Although the latter study is complicated by issues of blood-
brain barrier penetration and accumulation of MAb in a restricted
compartment, longer MAb treatment regimens may be required
to eliminate alphavirus RNA in infected tissues.
A high percentage of CHIKV-infected individuals suffer from
chronic arthralgia (13, 14, 16, 17, 58, 59), and chronic CHIKV
disease can be debilitating with severe economic consequences
(17, 58, 60, 61). Accordingly, an improved understanding of the
molecular mechanisms of chronic CHIKV disease and the devel-
opment of effective therapies to prevent or treat viral persistence
are critical. Our studies report a mouse model with long-term
CHIKV infection and pathology localized in joint-associated tis-
sues. In this model, adaptive immune responses control rather
than contribute to the severity of tissue pathology by restricting
CHIKV infection in most but not all tissues. Prophylaxis with a
combination of MAbs effectively prevents persistent CHIKV in-
fection, whereas therapeutic administration diminished infec-
tious virus burdens in tissues. The development of this model will
facilitate future studies to increase our understanding of the bio-
logical basis of chronic CHIKV infection and disease and allow a
cost-effective platform for testing new therapies that mitigate in-
fection and pathology.
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